Publication date: Jun 24, 2025
There are limited data exploring the outcome following SARS-CoV-2 infection in fibrotic interstitial lung disease (fILD). Our goal was to determine the association of vaccination for SARS-CoV-2 with both SARS-CoV-2 infection and subsequent 90-day mortality in fILD. Our second objective was to determine the association of immunosuppressive use with both SARS-CoV-2 infection and subsequent 90-day mortality in fILD. Patients with fILD enrolled in the Canadian Registry for Pulmonary Fibrosis with comprehensive access to data on SARS-CoV-2 vaccination and PCR-confirmed infection were included. Associations of vaccination status and current immunosuppressant use with SARS-CoV-2 infection and subsequent 90-day mortality were tested using Fisher’s exact test and subsequently multivariable logistic regression adjusting for age, sex, pre-identified comorbidities, forced vital capacity and diffusing capacity of the lung for carbon monoxide. Of 1452 total patients with fILD, 138 tested positive for SARS-CoV-2. On adjusted analysis, vaccination for SARS-CoV-2 was associated with a 60% reduction in the odds of infection (OR 0. 40, 95% CI 0. 24 to 0. 67 p
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | immunosuppression |
| disease | MESH | SARS-CoV-2 infection |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | interstitial lung disease |
| disease | MESH | Pulmonary Fibrosis |
| disease | MESH | infection |
| drug | DRUGBANK | Carbon monoxide |